Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Johnson & JohnsonNYSE: JNJ

Net Receivables · Q3 FY2026 · quarter ended Sep 2026

Net receivables rises 7.8% from a year ago

Net receivables stood at $18.99B at the end of Q3 FY2026, up 7.8% from a year earlier and down 0.3% from the prior quarter. Over 3 fiscal years it compounded at +0.5% a year.

Context

  • Net receivables amounted to 9.6% of total assets at the end of Q3 FY2026, up 0.5 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +7.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$18.99B-0.3% QoQ
Last fiscal yearDec 2025
$17.18B-9.2% YoY
Year agoSep 2025
$17.61B+7.8% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.8%——
1 year-9.2%——
3-year CAGR+0.5%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
17.18B USD
Year-over-year change
-9.2%
4-year CAGR
-2.5%

Net Receivables vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.8% is the 5th highest of 11, against a peer median of +6.7%.
  • Net receivables amounts to 9.6% of total assets for JNJ, versus a peer median of 10.2%.
JNJ Competitors
Net Receivables for JNJ and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JNJJohnson & JohnsonSep 2026$18.99B USD+7.8%+0.5%9.6%
AZNAstraZeneca PLCSep 2026$16.35B USD+14.0%+18.2%13.7%
ABBVAbbVie Inc.Jun 2026$13.82B USD+9.4%+3.8%10.2%
MRKMerck & Co., Inc.Jun 2026$12.56B USD+6.1%+10.3%9.7%
PFEPfizer Inc.Jun 2026$12.49B USD-22.4%+2.9%6.2%
BMYBristol-Myers Squibb CompanyJun 2026$10.55B USD-30.1%+1.4%12.0%
AMGNAmgen Inc.Jun 2026$10.23B USD+17.5%+14.4%10.7%
NVSNovartis AGJun 2026$9.85B USD+7.4%+3.4%8.1%
SNYSanofiJun 2026€9.21B EUR+12.2%+0.9%7.1%
GSKGSK plcJun 2026£8.03B GBP-23.9%+7.6%13.1%
GILDGilead Sciences, Inc.Jun 2026$5.06B USD+5.7%+0.9%10.2%
Peer median (excluding JNJ) —+6.7%+3.6%10.2%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents14.49B12.89B21.86B24.11B19.71B
Short-term Investments17.12B9.39B1.07B417M393M
Net Receivables18.98B16.92B14.87B18.93B17.18B
Inventory10.39B10.27B11.18B12.44B14.19B
Other Current Assets(3.7B)5.83B004.15B
Total Current Assets60.98B55.29B53.5B55.89B55.62B
Property, Plant & Equipment (Net)18.96B17.98B19.9B20.52B23.17B
Goodwill35.25B36.05B36.56B44.2B48.77B
Intangible Assets46.39B38.49B34.18B37.62B50.4B
Long-term Investments00000
Tax Assets10.22B8.95B9.28B10.46B6.87B
Other Non-current Assets10.22B30.62B14.15B11.41B14.37B
Total Non-current Assets121.04B132.08B114.06B124.21B143.59B
Total Assets182.02B187.38B167.56B180.1B199.21B
Account Payables11.06B9.89B9.63B10.31B11.99B
Short-term Debt3.77B12.76B3.45B5.98B8.5B
Tax Payables1.11B2.22B2.99B3.77B0
Deferred Revenue00000
Other Current Liabilities3.59B6.64B3.99B4.13B4.53B
Total Current Liabilities45.23B55.8B46.28B50.32B54.13B
Long-term Debt29.99B26.89B25.88B30.65B39.44B
Deferred Tax Liabilities7.49B3.99B3.19B2.45B6.79B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities25.3B23.9B23.43B25.19B17.31B
Total Non-current Liabilities62.77B54.77B52.5B58.29B63.54B
Total Liabilities108B110.57B98.78B108.61B117.67B
Common Stock3.12B3.12B3.12B3.12B3.12B
Retained Earnings123.06B128.35B153.84B155.79B168.98B
Accumulated OCI(13.06B)(12.97B)(12.53B)(11.74B)(14.93B)
Other Stockholders Equity(123.06B)(128.35B)(153.84B)00
Minority Interest00000
Total Equity74.02B76.8B68.77B71.49B81.54B
Total Debt33.75B39.64B29.33B36.63B47.93B
Net Debt19.26B26.75B7.47B12.53B28.22B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.